Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma

For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood. The DUO trial studied the head-to-head comparison of duvelisib versus ofatumumab, an approved standard-of-care chemotherapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). According to […]

Continue reading »

FDA approves CAR T therapy for large B-cell lymphoma

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy. Today’s approval includes treatment of diffuse large B-cell lymphoma (DLBCL) – the most […]

Continue reading »

Understanding how leukemia and lymphoma cells resist treatment

In a study published in Nature Communications, a team led IRCM Hematopoiesis and Cancer Research Unit director Tarik Möröy reveals how the GFI1 protein sometimes helps leukemia and lymphoma cancer cells evade therapy. This discovery could eventually help orient patients towards more effective treatment by considering the particular characteristics of their disease. In this Q&A, Möröy and his team offer […]

Continue reading »